Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000668)

(Analysis AN001022)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
plasmenyl-PE 38:1; [M-H]-@8.31	ME182726	1.07	0.50	5.36	0.83	0.15	0.19
PC 38:4; [M-Ac-H]-@5.56	ME182661	0.61	3.06	0.25	1.73	0.54	0.62
plasmenyl-PE 38:2; [M-H]-@7.96	ME182727	0.93	1.72	2.63	1.05	0.48	0.33
PC 30:0; [M-Ac-H]-@6.11	ME182633	0.84	0.71	2.21	0.83	1.32	0.82
PE 32:1; [M-H]-@6.29	ME182674	0.68	0.55	2.23	1.26	1.03	1.36
PC 32:1; [M-Ac-H]-@6.26	ME182636	0.76	0.78	1.77	1.91	0.89	0.81
lysoPE 22:4; [M-H]-@1.93	ME182714	0.92	1.10	1.68	1.39	0.84	0.64
lysoPE 22:5; [M-H]-@1.61	ME182715	0.91	1.00	1.59	1.37	0.83	0.83
lysoPE 20:3; [M-H]-@1.67	ME182711	0.90	0.97	1.54	1.63	0.67	0.89
lysoPE 20:5; [M-H]-@1.07	ME182713	0.92	0.93	1.33	1.77	0.76	0.74
PC 28:0; [M-Ac-H]-@5.41	ME182632	0.86	0.78	1.35	1.02	1.74	0.51
PC 30:1; [M-Ac-H]-@5.58	ME182634	0.78	0.85	1.24	1.00	1.66	0.82
PE 40:6; [M-H]-@6.94	ME182692	1.13	0.61	0.86	0.62	1.09	1.24
CL 82:13; [M-2H](2-)@6.39	ME182619	1.28	0.55	0.73	0.48	0.87	1.34
PE 38:6; [M-H]-@6.28	ME182690	1.12	0.62	0.57	0.56	1.08	1.48
PE 40:7; [M-H]-@6.43	ME182693	1.21	0.70	0.56	0.45	0.94	1.44
plasmenyl-PE 40:4; [M-H]-@7.84	ME182733	0.81	1.69	1.16	1.15	0.82	0.92
PE 40:8; [M-H]-@5.97	ME182694	1.23	0.65	1.19	0.67	0.88	1.01
lysoPE 18:1; [M-H]-@1.85	ME182709	1.02	0.98	1.31	0.96	0.65	1.26
PG 36:2; [M-H]-@5.99	ME182697	1.10	0.61	1.50	0.96	0.75	1.13
plasmenyl-PE 34:3; [M-H]-@6.35	ME182720	1.06	1.08	1.93	1.02	0.61	0.74
lysoPE 16:0; [M-H]-@1.69	ME182707	1.04	0.94	1.96	0.96	0.80	0.74
lysoPE 18:0; [M-H]-@2.50	ME182708	1.05	1.02	1.81	0.82	0.89	0.73
PC 32:0; [M-Ac-H]-@6.79	ME182635	0.98	0.84	1.59	0.97	0.97	0.95
PC 38:2; [M-Ac-H]-@7.71	ME182658	0.97	0.96	1.47	1.00	0.83	1.08
PC 35:4; [M-Ac-H]-@6.05	ME182647	1.00	1.00	1.44	0.80	1.00	0.93
PE 40:5; [M-H]-@7.16	ME182691	0.98	0.81	1.53	0.77	1.16	0.96
PC 33:0; [M-Ac-H]-@6.98	ME182638	0.90	0.90	1.74	1.04	1.13	0.79
PC 33:1; [M-Ac-H]-@6.57	ME182639	0.87	0.72	1.55	0.98	1.33	0.95
CL 70:1; [M-2H](2-)@6.86	ME182615	0.95	0.64	1.13	0.95	1.26	1.11
PE 34:1; [M-H]-@6.89	ME182676	0.90	0.65	0.92	1.14	1.26	1.18
PE 36:4; [M-H]-@6.28	ME182684	0.99	0.67	0.83	1.04	1.33	0.96
PC 32:2; [M-Ac-H]-@5.78	ME182637	1.01	0.88	1.24	0.98	1.19	0.73
PC 35:2; [M-Ac-H]-@6.73	ME182646	1.06	0.94	1.26	0.90	1.17	0.63
CL 70:5; [M-2H](2-)@6.06	ME182616	1.11	0.78	1.23	1.16	1.01	0.64
PE 34:3; [M-H]-@6.06	ME182678	1.18	0.63	1.04	1.19	0.97	0.69
PC 34:4; [M-Ac-H]-@5.65	ME182644	1.04	0.85	0.94	0.98	1.23	0.80
PE 37:4; [M-H]-@6.71	ME182686	1.13	0.75	1.02	0.85	1.13	0.81
PE 34:2; [M-H]-@6.43	ME182677	1.05	0.66	0.99	1.16	1.24	0.74
PE 35:2; [M-H]-@6.72	ME182679	1.07	0.54	1.15	1.07	1.16	0.87
plasmenyl-PE 36:5; [M-H]-@6.35	ME182725	1.05	0.83	0.59	1.43	0.95	0.93
PI 36:4; [M-H]-@5.12	ME182701	0.91	0.81	0.82	1.57	0.95	1.09
PI 38:3; [M-H]-@6.04	ME182703	0.86	1.03	0.94	1.43	1.00	1.04
PC 36:1; [M-Ac-H]-@7.55	ME182648	0.88	1.00	1.31	1.33	0.96	0.95
PC 35:1; [M-Ac-H]-@7.25	ME182645	0.91	0.84	1.25	1.12	1.13	1.00
PC 34:1; [M-Ac-H]-@6.85	ME182641	0.91	0.78	1.19	1.26	1.09	1.01
PC 38:3; [M-Ac-H]-@7.31	ME182659	0.95	0.85	1.12	1.26	1.01	0.98
PC 40:4; [M-Ac-H]-@7.52	ME182668	0.91	0.83	1.12	1.28	1.07	0.99
PI 38:5; [M-H]-@5.26	ME182705	0.96	0.90	1.11	1.18	0.91	1.10
PC 34:3; [M-Ac-H]-@5.90	ME182643	0.95	0.99	1.13	1.24	0.94	0.94
PC 38:5; [M-Ac-H]-@6.50	ME182662	0.95	1.00	1.06	1.25	0.96	0.94
PE 38:3; [M-H]-@7.26	ME182687	0.95	0.70	1.25	1.11	0.97	1.19
PI 34:1; [M-H]-@5.59	ME182698	0.80	0.77	1.31	1.34	1.03	1.25
PC 36:5; [M-Ac-H]-@5.80	ME182652	0.93	0.81	1.14	1.63	0.83	0.94
PE 36:5; [M-H]-@6.05	ME182685	0.87	0.58	1.37	1.59	0.89	1.14
plasmenyl-PE 34:0; [M-H]-@7.27	ME182717	0.91	1.22	1.18	0.79	0.98	1.18
FFA(22:3)	ME182626	0.99	1.27	1.12	0.67	0.98	1.03
FFA(24:1)	ME182628	1.00	1.34	1.04	0.68	0.84	1.14
plasmenyl-PE 36:1; [M-H]-@7.80	ME182721	1.00	1.31	0.95	0.88	0.80	1.09
FFA(24:2)	ME182629	1.08	1.32	0.94	0.68	0.90	0.93
PC 39:4; [M-Ac-H]-@7.26	ME182666	1.03	1.39	0.97	0.76	0.91	0.91
FFA(24:0)	ME182627	1.00	1.46	1.15	0.90	0.83	0.82
PG 36:0; [M-H]-@6.80	ME182696	0.97	1.22	1.14	1.05	0.80	1.03
FFA(Arachidonic acid)	ME182631	0.96	1.34	1.13	0.97	0.89	0.92
lysoPE 20:4; [M-H]-@1.38	ME182712	1.00	1.31	1.06	1.04	0.81	0.91
PI 34:2; [M-H]-@5.13	ME182699	1.01	1.14	0.86	1.21	0.78	1.01
plasmenyl-PE 36:3; [M-H]-@6.91	ME182723	0.97	1.18	0.87	1.13	0.89	1.02
PC 37:2; [M-Ac-H]-@7.38	ME182654	1.00	1.03	1.10	1.09	0.78	1.12
PE 34:0; [M-H]-@7.31	ME182675	1.01	1.05	1.03	0.92	0.98	1.01
PG 34:0; [M-H]-@6.20	ME182695	0.99	1.02	1.01	0.96	1.00	1.04
FFA(20:0)	ME182620	1.03	1.02	1.11	1.00	0.93	0.93
PI 37:4; [M-H]-@5.48	ME182702	1.00	1.13	1.09	0.96	0.89	1.01
lysoPE 18:2; [M-H]-@1.40	ME182710	1.00	1.24	1.35	1.28	0.78	0.66
PC 34:0; [M-Ac-H]-@7.44	ME182640	0.92	1.23	1.52	1.02	0.93	0.83
FFA(22:0)	ME182623	0.99	1.24	1.29	1.03	0.86	0.83
plasmenyl-PE 38:3; [M-H]-@7.58	ME182728	0.97	1.13	1.37	0.97	0.98	0.82
FFA(24:3)	ME182630	1.22	1.20	1.02	0.76	0.60	0.90
CL 74:7; [M-2H](2-)@6.13	ME182618	1.21	0.95	1.27	0.84	0.71	0.80
PE 36:0; [M-H]-@7.92	ME182680	1.12	1.11	1.33	0.76	0.77	0.88
FFA(22:1)	ME182624	1.07	1.33	1.47	0.80	0.75	0.76
FFA(22:2)	ME182625	1.10	1.23	1.46	0.51	0.84	0.89
PC 42:4; [M-Ac-H]-@8.30	ME182672	1.09	1.25	1.23	0.66	0.92	0.83
plasmenyl-PE 40:6; [M-H]-@7.22	ME182735	1.08	1.26	0.64	0.91	0.70	1.17
plasmenyl-PE 42:5; [M-H]-@7.92	ME182736	0.93	1.52	0.65	0.78	0.92	1.22
plasmenyl-PE 38:6; [M-H]-@6.60	ME182732	1.11	0.97	0.45	0.75	1.07	1.15
PI 38:6; [M-H]-@5.03	ME182706	1.16	0.64	0.59	0.89	1.04	1.13
PE 36:3; [M-H]-@6.57	ME182683	1.09	0.82	0.67	1.00	0.94	1.14
PC 36:6; [M-Ac-H]-@5.57	ME182653	1.02	0.86	0.71	0.96	1.05	1.19
PE 38:5; [M-H]-@6.54	ME182689	1.02	0.76	0.77	0.93	1.10	1.19
PC 42:5; [M-Ac-H]-@7.72	ME182673	1.09	0.85	0.70	0.80	1.14	1.03
PE 38:4; [M-H]-@6.98	ME182688	1.03	0.80	0.76	0.96	1.18	1.03
PC 40:7; [M-Ac-H]-@6.33	ME182670	0.99	0.99	0.78	0.79	1.04	1.29
PC 40:6; [M-Ac-H]-@6.87	ME182669	1.14	0.82	0.63	0.67	1.08	1.15
PC 38:6; [M-Ac-H]-@6.13	ME182664	1.08	0.80	0.71	0.76	1.06	1.23
PC 38:6; [M-Ac-H]-@6.31	ME182663	1.08	0.80	0.71	0.76	1.06	1.23
plasmenyl-PE 36:2; [M-H]-@7.36	ME182722	1.03	1.22	0.89	0.92	0.95	0.94
plasmenyl-PE 34:1; [M-H]-@7.21	ME182718	1.05	1.00	0.76	0.91	1.00	1.05
plasmenyl-PE 40:5; [M-H]-@7.39	ME182734	1.11	1.06	0.72	0.88	1.03	0.85
plasmenyl-PE 38:4; [M-H]-@7.27	ME182729	1.06	1.15	0.73	0.88	0.99	0.97
plasmenyl-PE 38:4; [M-H]-@7.37	ME182730	1.06	1.15	0.73	0.88	0.99	0.97
PC 37:5; [M-Ac-H]-@6.19	ME182657	0.96	1.02	0.65	1.14	1.16	0.95
PC 38:4; [M-Ac-H]-@6.92	ME182660	0.99	0.93	1.02	1.04	1.06	0.97
PC 36:2; [M-Ac-H]-@7.03	ME182649	1.04	0.88	0.90	0.95	1.03	1.05
PC 36:3; [M-Ac-H]-@6.55	ME182650	1.02	0.89	0.83	1.07	1.04	1.02
PC 34:2; [M-Ac-H]-@6.34	ME182642	1.00	0.97	0.89	1.03	1.03	1.03
plasmenyl-PE 34:2; [M-H]-@6.76	ME182719	0.95	0.96	0.94	1.06	1.06	1.07
PC 36:4; [M-Ac-H]-@6.22	ME182651	0.95	0.95	0.89	1.04	1.20	0.96
PC 37:3; [M-Ac-H]-@6.91	ME182655	0.92	1.00	0.89	0.93	1.17	1.11
PE 36:2; [M-H]-@7.03	ME182682	1.05	0.85	0.78	1.20	0.94	1.02
CL 74:1; [M-2H](2-)@7.51	ME182617	1.01	0.96	0.69	1.06	0.92	1.20
PE 36:1; [M-H]-@7.48	ME182681	0.97	0.92	0.67	1.08	0.99	1.27
plasmenyl-PE 36:4; [M-H]-@6.69	ME182724	0.91	1.00	0.67	1.13	1.01	1.28
PC 40:8; [M-Ac-H]-@5.89	ME182671	0.91	1.00	0.92	1.19	0.97	1.15
PI 38:4; [M-H]-@5.79	ME182704	0.93	0.97	0.83	1.11	1.06	1.12
plasmenyl-PE 38:5; [M-H]-@6.77	ME182731	0.95	1.02	0.74	1.12	0.99	1.17
PC 38:7; [M-Ac-H]-@5.61	ME182665	1.04	0.87	0.85	1.03	0.90	1.16
PI 36:2; [M-H]-@5.81	ME182700	1.02	1.01	0.83	1.09	0.91	1.07
PC 37:4; [M-Ac-H]-@6.67	ME182656	0.96	1.16	0.89	0.76	1.29	0.88
FFA(20:1)	ME182621	1.14	1.17	0.69	0.50	1.08	0.97
PC 39:6; [M-Ac-H]-@6.54	ME182667	1.18	1.32	0.66	0.47	1.02	0.84
FFA(20:2)	ME182622	1.20	1.11	0.85	0.54	1.01	0.83
lysoPE 22:6; [M-H]-@1.33	ME182716	1.15	1.14	0.83	0.74	0.92	0.87

Factors:

F1	Diet intervention:Baseline \| Gender:female
F2	Diet intervention:Baseline \| Gender:male
F3	Diet intervention:Overfeeding-2 weeks \| Gender:female
F4	Diet intervention:Overfeeding-2 weeks \| Gender:male
F5	Diet intervention:Saturated Fatty Acid \| Gender:female
F6	Diet intervention:Unsaturated Fatty Acid \| Gender:female

Data matrix